Welcome to our dedicated page for Pacira Biosciences news (Ticker: PCRX), a resource for investors and traders seeking the latest updates and insights on Pacira Biosciences stock.
Pacira BioSciences reports developments across a commercial portfolio of non-opioid pain management and regenerative health products. Its recurring updates center on EXPAREL® (bupivacaine liposome injectable suspension) for postsurgical pain, ZILRETTA® extended-release intra-articular corticosteroid injection for osteoarthritis, and the iovera° cold-therapy device for targeted nerve pain control.
Company news also covers earnings and product revenue trends, real-world evidence on opioid use and healthcare costs, pipeline development involving ZILRETTA, iovera° and PCRX-201, share repurchases, equity inducement awards, and stockholder governance matters tied to board composition and proxy materials.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Pacira BioSciences, Inc. (NASDAQ:PCRX) will report its first quarter financial results on May 3, 2023, before U.S. market opening. A conference call is scheduled for 8:30 a.m. ET the same day. Participants may pre-register for Q&A via telephone to receive dial-in details. The event will also be available as a live webcast. Pacira focuses on non-opioid pain management solutions and offers three commercial products: EXPAREL®, ZILRETTA®, and ioveraº®. These innovative interventions aim to reduce dependence on opioids and address various pain-related conditions.
Pacira BioSciences, Inc. has partnered with the Invited Celebrity Classic, a PGA TOUR Champions event, to promote non-opioid pain management using its device, iovera°. The device applies targeted cold therapy to alleviate chronic and acute pain without medications. Paul Goydos, a professional golfer, joins as a brand ambassador to raise awareness of iovera°.
The partnership includes on-site activations and education at various golf tournaments throughout the year, with the inaugural event occurring from April 21-23, 2023, at the Las Colinas Country Club. This initiative aims to highlight the benefits of non-opioid options and reduce reliance on opioid medications, which carry substantial addiction risks. Pacira currently focuses on redefining pain management through innovation.
Pacira BioSciences, Inc. (NASDAQ: PCRX) announced the appointment of Christopher Young as Chief Manufacturing Officer on April 19, 2023. Young, a seasoned operations executive, will oversee all manufacturing activities for Pacira's product portfolio, focusing on supply chain design, product life cycle management, and global product launches. Prior to joining Pacira, he held senior roles at Akorn Inc. and Alvogen Inc., demonstrating a strong track record in operational leadership and efficiency improvements. CEO Dave Stack praised Young for his team-building skills and operational expertise. Young expressed enthusiasm for contributing to Pacira's vision of providing opioid alternatives and enhancing patient care.